No­vo ex­pands pact with Flag­ship's Va­lo to in­clude obe­si­ty, di­a­betes for $190M near-term

No­vo Nordisk is dou­bling down on its com­pu­ta­tion­al biotech part­ner Va­lo Health, ex­pand­ing their col­lab­o­ra­tion from 11 po­ten­tial drugs to 20.

Wednes­day morn­ing’s ex­tend­ed pact …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER